Form 6-K Regencell Bioscience For: Mar 30

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of March 2026

 

Commission File Number: 001-40617

 

Regencell Bioscience Holdings Limited

(Registrant’s Name)

 

9/F Chinachem Leighton Plaza

29 Leighton Road

Causeway Bay, Hong Kong

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

 

Form 20-F ☒      Form 40-F ☐

 

 

 

EXHIBIT INDEX

 

Exhibit No.		Description of Exhibit
99.1		Press Release – Regencell Bioscience Holdings Limited Announces At-the-Market Offering of Ordinary Shares

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Date: March 30, 2026

 

	Regencell Bioscience Holdings Limited
	By:	/s/ Yat-Gai Au
	Name:	Yat-Gai Au
	Title:	Chief Executive Officer and
		Chairman of the Board of Directors

 

[Signature Page to Form 6-K]

 

 

ATTACHMENTS / EXHIBITS

PRESS RELEASE - REGENCELL BIOSCIENCE HOLDINGS LIMITED ANNOUNCES AT-THE-MARKET OFFERING OF ORDINARY SHARES

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Boba Mint Holdings Launches HeatCheck Gaming to Develop Casino Games on Stake
• Open Road Resorts Expands into Kentucky with Acquisition of Elkhorn Creek RV Park in Frankfort
• Survey Shows Nearly Half of Central Banks to Ramp Up Gold Reserves